Top Markets
#1 Islamic Coin Islamic Coin +154.45%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +23.10%
#4 MarsCoin MarsCoin +14.90%
#5 BOOK OF MEME BOOK OF MEME +14.69%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.37%
#7 Nockchain Nockchain +11.14%
#8 Starpower Starpower +9.36%
#9 Venom Venom +9.22%
#10 Lighter Lighter +9.20%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Kedudukan dalam Saham #28047
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Harga Saham
$0.55
Disegerakkan terakhir: 2025-02-11
Modal Pasaran
$28.90M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Marinus Pharmaceuticals, Inc. (MRNS)

Kategori

Healthcare
Nisbah P/E bagi Marinus Pharmaceuticals, Inc. (MRNS)
Nisbah P/E pada August 2026 TTM: -0.21
Menurut laporan kewangan dan harga saham terkini Marinus Pharmaceuticals, Inc., nisbah P/E semasa (TTM) ialah -0.21. Pada akhir 2022, syarikat mempunyai nisbah P/E sebanyak -1.96.
Sejarah nisbah P/E bagi Marinus Pharmaceuticals, Inc. dari 2012 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) -0.21 -79.70%
2023 -1.03 -47.31%
2022 -1.96 83.00%
2021 -1.07 -14.10%
2020 -1.25 127.96%
2019 -0.55 -31.48%
2018 -0.80 -68.56%
2017 -2.54 1,378.30%
2016 -0.17 -85.01%
2015 -1.15 -23.59%
2014 -1.50 -50.96%
2013 -3.06 -73.27%
2012 -11.45 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -14,064.75%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 3,694.74%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -14,743.33%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -15,624.10%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.